4Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic,pharmacodynamic,and clinical outcomes[J]. Circulation, 2009,119 (19) :2553-2560.
5Storey RF. Pharmacology and clinical trials of reversibly- binding P2Y12 inhibitors [J]. Thromb Haemost, 2011, 105 (Suppl 1) :S75-81.
6Cheng JWM. Ticagrelor: oral reversible P2Y ( 12 ) receptor antagonist for the management of acute coronary syndromes [J]. Clin Ther, 2012,34(6) : 1209-1220.
7Wallentin L, Richard BC, Budai A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2009,361(11) :1045-1057.
8Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with planned invasive strategy for acute coronary syndromes ( PLATO ): a randomized double-blind study[J]. Lancet, 2010, 375 (9711) : 283-293.
9James SK, Row MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomized platelet inhibition and patient outcomes (PLATO) trial[J]. BMJ, 2011,342 : d3527.
10Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial[J]. J Am Coll Cardiol,2011,57(6) :672-684;.
